Acrivon cuts IPO price to raise $99M for plan to revive old Lilly cancer drug
BioPharma
Stay updated with breaking news from Array Biopharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
WATERTOWN, Mass., Nov. 03, 2022 -- Kymera Therapeutics, Inc. , a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader... | November 3, 2022
WATERTOWN, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing...
Leadership Team Continues to Expand with Addition of Key Leader in Clinical OperationsMINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appoint...